Ovarian Cancer Treatment in India & UAE
Expert ovarian cancer treatment — cytoreductive surgery, carboplatin + paclitaxel chemotherapy, PARP inhibitors, and HIPEC. Costs 65–75% lower in India than the USA.
Estimated cost: $4,000 – $9,000 · Average stay: 7–10 days
Ovarian cancer is the fifth most common gynecologic malignancy worldwide and the leading cause of gynecologic cancer death, primarily because most cases are diagnosed at an advanced stage when symptoms become apparent. Approximately 300,000 women are diagnosed with ovarian cancer annually. Despite this challenging epidemiology, modern treatment has significantly improved survival — particularly with the advent of PARP inhibitors and anti-angiogenic agents that extend progression-free survival in women with BRCA-mutant and other ovarian cancers.
The cornerstone of ovarian cancer treatment is a combination of radical cytoreductive surgery — aimed at removing all visible tumor from the peritoneal cavity — followed by platinum-based chemotherapy. The quality of surgical debulking is one of the strongest predictors of outcome: patients with no residual disease after surgery (R0 resection) have dramatically better survival than those with residual tumor.
India's leading gynecologic oncology centers perform high volumes of cytoreductive surgery, including complex procedures such as diaphragm stripping, bowel resection, and hyperthermic intraperitoneal chemotherapy (HIPEC), with outcomes comparable to specialized Western cancer centers. Treatment costs are 65–75% lower than equivalent care in the USA.
Gaf Healthcare connects international ovarian cancer patients with India's and UAE's most experienced gynecologic oncologists, ensuring expert surgical debulking and access to the latest targeted therapies.
Types of Ovarian Cancer and Staging
Ovarian cancer encompasses several histologic subtypes with distinct behaviors and treatment responses:
High-grade serous ovarian cancer (HGSOC) is the most common and aggressive subtype, accounting for 70% of cases. It is closely associated with BRCA1/2 mutations and typically presents at stage III or IV. HGSOC is highly chemosensitive but frequently recurs.
Low-grade serous carcinoma grows more slowly, is less chemosensitive, and may respond to hormonal therapy.
Endometrioid, mucinous, and clear cell carcinomas have distinct molecular profiles and treatment considerations.
Staging follows the FIGO system:
- Stage I: Cancer confined to one or both ovaries. 5-year survival: 85–95%.
- Stage II: Extension to pelvic organs. 5-year survival: 70–80%.
- Stage III: Spread to abdominal peritoneum or regional lymph nodes. 5-year survival: 39–59%.
- Stage IV: Distant metastasis. 5-year survival: 17–29%.
BRCA1 and BRCA2 mutation testing is standard — BRCA-mutant cancers have superior responses to platinum chemotherapy and PARP inhibitors.
Who Needs Ovarian Cancer Treatment?
All patients with confirmed ovarian cancer require treatment. The approach differs by stage and timing.
Primary cytoreductive surgery (upfront surgery): preferred for patients with stage III–IV disease who are deemed fit for surgery and where complete or near-complete tumor removal is achievable. A gynecologic oncologist — not a general surgeon — must perform the debulking to achieve optimal outcomes.
Neoadjuvant chemotherapy (NACT) followed by interval debulking: preferred for patients with very bulky disease unlikely to be optimally debulked upfront, or patients not fit for primary surgery. Three cycles of carboplatin + paclitaxel are given before surgery, then surgery, then three more cycles post-operatively.
Adjuvant chemotherapy: all stage II–IV patients receive platinum-based chemotherapy (carboplatin + paclitaxel, 6 cycles) after optimal debulking.
Maintenance therapy: after first-line chemotherapy, PARP inhibitors (olaparib for BRCA-mutant cancers; niraparib for all-comers) are used as maintenance therapy to delay recurrence — a major advance in extending progression-free survival.
Ovarian Cancer Surgery and Chemotherapy
Cytoreductive surgery — removing all visible tumor from the abdominal and pelvic cavity — is the single most important prognostic factor in ovarian cancer. Surgery includes total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, peritoneal stripping, lymph node sampling, and — when needed — diaphragm stripping, bowel resection, splenectomy, or liver surface resection.
The goal is R0 resection (no visible residual disease). Patients with R0 resection have a median overall survival that is 2–3 times longer than those with residual disease.
Hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly used at interval debulking surgery. After achieving optimal cytoreduction, heated cisplatin solution (41–43°C) is circulated through the abdominal cavity for 90 minutes to eliminate microscopic tumor deposits. HIPEC has shown improved overall survival in the OVHIPEC trial.
Post-surgical chemotherapy: carboplatin (AUC 5) + paclitaxel (175 mg/m²) administered every 3 weeks for 6 cycles is the standard first-line regimen. Bevacizumab is added for high-risk stage III–IV disease. PARP inhibitor maintenance follows chemotherapy completion.
Procedure Steps
- Diagnostic workup: pelvic ultrasound, CT chest/abdomen/pelvis, CA-125 tumor marker, and biopsy if indicated.
- BRCA1/2 genetic testing and HRD (homologous recombination deficiency) testing — guides maintenance therapy selection.
- Multidisciplinary tumor board assessment of surgical resectability vs neoadjuvant chemotherapy first.
- Primary cytoreductive surgery or neoadjuvant chemotherapy (3 cycles carboplatin + paclitaxel).
- Interval debulking surgery (if NACT approach) with HIPEC if available and indicated.
- Adjuvant platinum-based chemotherapy: 6 cycles carboplatin + paclitaxel ± bevacizumab.
- Maintenance therapy: olaparib (BRCA-mutant) or niraparib (all-comers) for 2 years after chemotherapy.
- Surveillance: CA-125 every 3 months; CT every 6 months for 2 years.
Ovarian Cancer Treatment Approaches
Primary Cytoreductive Surgery
Radical surgical debulking with the goal of removing all visible peritoneal disease. Includes hysterectomy, oophorectomy, omentectomy, and extended procedures as needed. Performed by a dedicated gynecologic oncologist trained in complex pelvic and abdominal surgery.
Cost: $5,000 – $10,000
HIPEC (Heated Intraperitoneal Chemotherapy)
Heated cisplatin circulated through the abdominal cavity after optimal surgical debulking to eliminate microscopic peritoneal tumor deposits. Associated with improved overall survival in clinical trial evidence. Available at specialized centers in India.
Cost: $8,000 – $15,000 (surgery + HIPEC)
Carboplatin + Paclitaxel Chemotherapy
The gold standard first-line chemotherapy regimen for ovarian cancer. Six cycles given every 3 weeks. Highly effective against high-grade serous carcinoma, with response rates exceeding 75–80%. Well tolerated with standard anti-nausea premedication.
Cost: $600 – $1,500 per cycle
PARP Inhibitor Maintenance (Olaparib / Niraparib)
Oral maintenance therapy taken daily for 2 years after first-line chemotherapy. Dramatically extends progression-free survival, particularly in BRCA-mutant cancers (olaparib reduces recurrence risk by 70% in BRCA-mutant patients). Available in India at a fraction of Western branded costs.
Cost: $800 – $2,000 per month
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
India — $4,000 – $9,000 — Save 65–75%
UAE — $7,000 – $14,000 — Save 50–60%
USA / UK — $20,000 – $60,000+ — Baseline
Ovarian cancer treatment in India costs 65–75% less than in the USA, with equivalent surgical outcomes performed by gynecologic oncologists trained at international fellowship programs. Olaparib (Lynparza) and niraparib (Zejula) are available as generics in India at dramatically reduced cost, making long-term maintenance therapy financially feasible for international patients.
Recovery & Follow-up
After cytoreductive surgery, hospital stay is typically 7–10 days. Recovery to full activity takes 6–8 weeks. Chemotherapy begins 4–6 weeks after surgery and runs for 4.5 months (6 cycles, every 3 weeks). Common side effects — hair loss, nausea, fatigue, peripheral neuropathy from paclitaxel — are managed proactively. Maintenance PARP inhibitor therapy is taken as a daily oral tablet for 2 years.
Recovery Tips
- Prioritize protein-rich nutrition during and after chemotherapy to support immune function and tissue healing.
- Neuropathy from paclitaxel — tingling or numbness in hands and feet — should be reported early; dose adjustments can minimize lasting nerve damage.
- Light activity such as walking is encouraged during chemotherapy to reduce fatigue and prevent blood clots.
- Take the PARP inhibitor exactly as prescribed — missing doses reduces the maintenance benefit.
- Monitor CA-125 every 3 months after treatment — a rising marker is the earliest sign of recurrence.
Risks & Complications
Cytoreductive surgery risks include bowel or urinary tract injury, anastomotic leak (if bowel resection performed), bleeding, infection, and deep vein thrombosis. HIPEC adds a small risk of renal toxicity from heated cisplatin. Chemotherapy risks include bone marrow suppression, nausea, hair loss, and peripheral neuropathy (paclitaxel). PARP inhibitors cause mild anemia, nausea, and fatigue in some patients.
Why GAF Healthcare
Gaf Healthcare identifies India's top gynecologic oncology programs with the highest cytoreductive surgery volumes — the most critical quality metric in ovarian cancer treatment. We facilitate second-opinion reviews of imaging by expert gynecologic oncologists, arrange priority surgical scheduling, and coordinate all post-surgical chemotherapy with continuous patient support.
Frequently Asked Questions
What is the survival rate for ovarian cancer?
Five-year survival by stage: Stage I — 85–95%, Stage II — 70–80%, Stage III — 39–59%, Stage IV — 17–29%. Patients with BRCA mutations have better chemotherapy response and benefit most from PARP inhibitor maintenance, with significantly extended progression-free survival.
What is HIPEC and is it available in India?
HIPEC (hyperthermic intraperitoneal chemotherapy) is a procedure where heated cisplatin is circulated through the abdominal cavity after optimal cytoreductive surgery. It is available at select tertiary cancer centers in India and has demonstrated improved overall survival in the OVHIPEC-1 randomized trial.
Do I need BRCA testing before starting treatment?
Yes. BRCA1/2 testing is strongly recommended for all ovarian cancer patients. BRCA mutation status guides maintenance therapy selection (olaparib vs niraparib) and identifies family members who may benefit from risk-reducing measures. Gaf Healthcare's partner hospitals perform germline and somatic BRCA testing.
How much does olaparib cost in India?
Generic olaparib (olumiant) is available in India at approximately $300–$600 per month, compared to $15,000+ per month for branded Lynparza in the USA. This makes 2-year maintenance therapy — which costs over $350,000 in the USA — financially accessible in India.
Can ovarian cancer be treated if detected at stage III?
Yes. Stage III ovarian cancer is treated with curative intent through optimal cytoreductive surgery plus 6 cycles of carboplatin + paclitaxel chemotherapy. Approximately 20–30% of stage III patients achieve long-term remission. PARP inhibitor maintenance further extends progression-free survival in most patients.